Industry ownership intelligence

Medical Devices insider conviction

Executive and director activity assessed across 83 companies for breadth, transaction quality, clustering, freshness, and directional conviction.

49/100

Balanced insider tape

83/100 confidence
Level
Industry
Evidence window
Latest 90 days
Named insiders
628
Latest evidence
24 Jul 2026

Capital positioning read

Balanced insider tape

Acquisition and disposal evidence is mixed after low-information compensation and derivative activity is separated out.

Wait for clearer clustering

Evidence in favour

  • 135 distinct acquisition events survive duplicate and security-type controls.
  • Participation spans 628 named insiders rather than one filing source.

Decision risks

  • Qualifying disposal events outnumber acquisitions, although disposals receive a lower directional weight.
Conviction49Balanced insider tape
Confidence83Deep evidence
Controlled events528directional common-share events
Company breadth83represented companies
Acquisition value$15.8Mnormalized amount
Disposal value$232.1Mnormalized amount

Flow regime

Twelve-week filing pressure

Shows the cadence and balance of the full filing tape.

30818 May
15825 May
30901 Jun
16008 Jun
15715 Jun
7922 Jun
11129 Jun
7006 Jul
4213 Jul
1920 Jul
027 Jul
003 Aug
AcquisitionsDisposalsScore 49 · Confidence 83

Relative positioning

Industry peer map

Current score with confidence.

Directional balance

Controlled event mix

25.6%acquisition
Acquisition events
135
Disposal events
393
Net value
-$216.3M

Evidence quality

What the filings represent

Common equity1080
Equity compensation310
Options and derivatives223
Other securities10

Decision makers

Role participation

Director867
Other executive302
CEO and chair158
Finance leadership129
Other or unspecified111
Large holder56

Quality controls

Evidence usability

Normalized values
35%
Priced common share
34%
Named insiders
628
Controlled events
528

Auditable evidence

Latest Medical Devices filings

Showing 661 to 690 of 1623.

INGNInogen Inc
RIDER, HEATHER D.Director
AcquisitionCommon equity
Not reportedContext evidence
INGNInogen Inc
SAHNEY, MIRA KIRTIDirector
AcquisitionCommon equity
Not reportedContext evidence
LUNGPulmonx Corp
BURNS, THOMAS WILLIAMDirector
AcquisitionCommon equity
Not reportedContext evidence
LUNGPulmonx Corp
FERRARI, RICHARDDirector
AcquisitionCommon equity
Not reportedContext evidence
LUNGPulmonx Corp
FLORIN, DANIEL PDirector
AcquisitionCommon equity
Not reportedContext evidence
LUNGPulmonx Corp
MEAD, DANA G JR.Director
AcquisitionCommon equity
Not reportedContext evidence
LUNGPulmonx Corp
MELENIKIOTOU, GEORGIADirector
AcquisitionCommon equity
Not reportedContext evidence
LUNGPulmonx Corp
SULLIVAN, TIFFANYDirector
AcquisitionCommon equity
Not reportedContext evidence
NPCENeuropace Inc
ANDRADE, LISADirector
AcquisitionCommon equity
Not reportedContext evidence
NPCENeuropace Inc
ANDRADE, LISADirector
AcquisitionOptions and derivatives
Not reportedContext evidence
NPCENeuropace Inc
FISCHER, FRANK MDirector
AcquisitionCommon equity
Not reportedContext evidence
NPCENeuropace Inc
FISCHER, FRANK MDirector
AcquisitionOptions and derivatives
Not reportedContext evidence
NPCENeuropace Inc
GEIGER, URIDirector
AcquisitionOptions and derivatives
Not reportedContext evidence
NPCENeuropace Inc
GEIGER, URIDirector
AcquisitionCommon equity
Not reportedContext evidence
NPCENeuropace Inc
HUENNEKENS, R SCOTTDirector
AcquisitionCommon equity
Not reportedContext evidence
NPCENeuropace Inc
HUENNEKENS, R SCOTTDirector
AcquisitionOptions and derivatives
Not reportedContext evidence
NPCENeuropace Inc
KUMAR, RAKHIDirector
AcquisitionCommon equity
Not reportedContext evidence
NPCENeuropace Inc
KUMAR, RAKHIDirector
AcquisitionOptions and derivatives
Not reportedContext evidence
NPCENeuropace Inc
RYAN, RENEEDirector
AcquisitionOptions and derivatives
Not reportedContext evidence
NPCENeuropace Inc
RYAN, RENEEDirector
AcquisitionCommon equity
Not reportedContext evidence
UFPTUFP Technologies Inc
BAILLY, R JEFFREYDirector, Executive Chairman
AcquisitionCommon equity
Not reportedContext evidence
GMEDGlobus Medical
DAVIDAR, DAVID DDirector
DisposalCommon equity
$2.0MDirectional evidence
GMEDGlobus Medical
DAVIDAR, DAVID DDirector
AcquisitionCommon equity
$656.8KDirectional evidence
BFLYButterfly Network Inc
CASHMAN, STEVEChief Business Officer
DisposalCommon equity
$520.1KDirectional evidence
STESTERIS plc
CARESTIO, DANIEL ADirector, President and CEO
DisposalCommon equity
$291.3KDirectional evidence
UFPTUFP Technologies Inc
BAILLY, R JEFFREYDirector, Executive Chairman
DisposalCommon equity
$167.9KDirectional evidence
SIBNSi-Bone Inc
DUNN, JEFFREY WDirector
DisposalCommon equity
$54.5KDirectional evidence
HAEHaemonetics Corporation
MILLER, LAURIE A.SVP, Human Resources
DisposalCommon equity
$22.3KDirectional evidence
MDTMedtronic PLC
BLOMQUIST, DENISE L.Chief Accounting Officer
DisposalCommon equity
$19.7KDirectional evidence
HAEHaemonetics Corporation
MAUNSELL, FARRIS MARYANNEVP, Chief Accounting Officer
DisposalCommon equity
$18.5KDirectional evidence

Group-level method

Breadth before headline value

Company breadth

A sector or industry score must be supported across companies. One very large filing cannot manufacture broad conviction.

Economic duplicates

Matching company, date, side, security class, share count, and value records are consolidated for the directional calculation.

Evidence hierarchy

Priced common-share activity determines direction. Compensation and derivative records are mapped separately so ownership mechanics remain visible.

Positioning use

The score identifies where insider alignment merits research or where disposal concentration needs review. Price, trend, valuation, and portfolio risk still decide positioning.

Independent market research for education. This classification is not investment advice, a recommendation, a forecast, or an execution instruction.

Evidence context